Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option Buying

Liquidia Corporation (NASDAQ:LQDA) saw unusually large options trading activity on Wednesday. Stock investors purchased 30,594 call options on the stock. This represents an increase of 108% compared to the average volume of 14,708 call options.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: The agreement removes a major overhang and allows YUTREPIA inhalation powder to remain commercially available for pulmonary arterial hypertension (PAH) patients. Liquidia will not appeal the recent patent ruling, bringing greater certainty to the product’s commercialization. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA sales totaled $222.7 million, contributing to $396.1 million of cash and cash equivalents at September 30. Management expects to fund the settlement and ongoing clinical programs through cash on hand and product sales without raising additional financing.
• Positive Sentiment: BTIG upgraded Liquidia to “buy” with a $70 price target, while Needham maintained a “buy” rating and set a $58 target. Both imply substantial upside from recent trading levels.
• Positive Sentiment: Call-option activity was unusually high, with 30,594 calls purchased—about 108% above typical daily volume—indicating increased speculative interest following the settlement.
• Neutral Sentiment: Multiple executives and other insiders sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested awards. The transactions reduce holdings but were not described as discretionary open-market sales, limiting their significance as a standalone signal.
• Negative Sentiment: Liquidia will pay United Therapeutics a net $380.7 million, including $175 million within 30 business days, $60.3 million related to antitrust claims and $145.4 million in two 2027 installments. The payments will significantly reduce the company’s cash cushion and could constrain investment.
• Negative Sentiment: The company is removing the PH-ILD indication from YUTREPIA’s label and will stop promoting Treprostinil Injection, narrowing potential revenue opportunities despite preserving the PAH business.

Insider Buying and Selling at Liquidia

In other news, insider Jason Adair sold 73,631 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $69.09, for a total transaction of $5,087,165.79. Following the transaction, the insider directly owned 174,606 shares in the company, valued at approximately $12,063,528.54. This trade represents a 29.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Katherine Rielly-Gauvin sold 36,789 shares of Liquidia stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $74.99, for a total transaction of $2,758,807.11. Following the transaction, the director directly owned 44,637 shares in the company, valued at approximately $3,347,328.63. The trade was a 45.18% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 745,194 shares of company stock worth $41,081,702. 25.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Bank of New York Mellon Corp purchased a new stake in Liquidia during the 2nd quarter worth $29,694,000. Bank of America Corp DE raised its position in Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the period. Capricorn Fund Managers Ltd purchased a new position in Liquidia in the first quarter valued at about $9,337,000. Eversept Partners LP raised its position in Liquidia by 33.0% in the first quarter. Eversept Partners LP now owns 677,392 shares of the company’s stock valued at $25,565,000 after purchasing an additional 167,949 shares during the period. Finally, Seven Fleet Capital Management LP lifted its stake in shares of Liquidia by 124.5% during the first quarter. Seven Fleet Capital Management LP now owns 204,876 shares of the company’s stock worth $7,732,000 after purchasing an additional 113,609 shares in the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on LQDA shares. Bank of America lifted their price target on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Jefferies Financial Group raised Liquidia to a “strong-buy” rating in a research report on Thursday, October 1st. Lifesci Capital downgraded Liquidia from an “outperform” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research report on Wednesday, August 12th. Finally, Piper Sandler set a $129.00 target price on Liquidia in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $79.69.

Liquidia Stock Up 25.1%

NASDAQ LQDA traded up $6.72 during trading on Wednesday, hitting $33.53. The company’s stock had a trading volume of 16,101,740 shares, compared to its average volume of 2,167,709. Liquidia has a fifty-two week low of $21.94 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The company has a market cap of $3.00 billion, a PE ratio of 24.81 and a beta of 0.61. The business’s 50 day simple moving average is $63.40 and its 200-day simple moving average is $61.76.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The company had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the firm posted ($0.49) EPS. The firm’s revenue for the quarter was up 1842.1% on a year-over-year basis. On average, equities analysts anticipate that Liquidia will post 2.05 EPS for the current fiscal year.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).